(Q34954738)

5 August 2017

1 reference

23 September 2020

First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence (English)

1 reference

antineoplastic combined chemotherapy protocols

5 August 2017

1 reference

1 reference

23 September 2020

1 reference

23 September 2020

1 reference

1 reference

J Sandercock

1

1 reference

5 August 2017

M K B Parmar

series ordinal

2

1 reference

5 August 2017

V Torri

series ordinal

3

1 reference

5 August 2017

W Qian

series ordinal

4

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

British Journal of Cancer

5 August 2017

7 October 2002

7 references

13 March 2019

14 March 2019

24 March 2019

3 April 2019

25 June 2019

29 May 2020

23 September 2020

7 references

5 August 2017

13 March 2019

14 March 2019

24 March 2019

3 April 2019

25 June 2019

23 September 2020

87

1 reference

5 August 2017

issue

8

1 reference

5 August 2017

page(s)

815-824

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6600567

5 August 2017

exact match

0 references

cites work

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Chemotherapy for ovarian cancer--a consensus statement on standard practice.

8 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600567

Explaining heterogeneity in meta-analysis: a comparison of methods.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600567

Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation).

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376171

Paclitaxel and cisplatin in ovarian cancer

26 October 2018

1 reference

12 December 2020

A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma

1 reference

12 December 2020

Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: a prospective randomized trial

1 reference

12 December 2020

Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study

1 reference

12 December 2020

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project

1 reference

12 December 2020

Long-term results of a randomized trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide, and adriamycin in advanced ovarian cancer. GICOG (Gruppo Interregionale Cooperativo Oncologico Ginecologia), Italy

1 reference

12 December 2020

Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer

1 reference

12 December 2020

Chemotherapy for ovarian cancer

1 reference

12 December 2020

Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a Hellenic co-operative oncology group study

1 reference

12 December 2020

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

12 December 2020

Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer

1 reference

12 December 2020

Good manners for the pharmaceutical industry

1 reference

12 December 2020

Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer

1 reference

12 December 2020

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study

1 reference

12 December 2020

Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer

1 reference

12 December 2020

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600567

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600567

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference